These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25128058)

  • 21. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations.
    Vreman RA; de Ruijter AS; Zawada A; Tafuri G; Stoyanova-Beninska V; O'Connor D; Naumann-Winter F; Wolter F; Mantel-Teeuwisse AK; Leufkens HGM; Sidiropoulos I; Larsson K; Goettsch WG
    Drug Discov Today; 2020 Jul; 25(7):1223-1231. PubMed ID: 32344040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
    Vella Bonanno P; Bucsics A; Simoens S; Martin AP; Oortwijn W; Gulbinovič J; Rothe C; Timoney A; Ferrario A; Gad M; Salem A; Hoxha I; Sauermann R; Kamusheva M; Dimitrova M; Petrova G; Laius O; Selke G; Kourafalos V; Yfantopoulos J; Magnusson E; Joppi R; Jakupi A; Bochenek T; Wladysiuk M; Furtado C; Marković-Peković V; Mardare I; Meshkov D; Fürst J; Tomek D; Cortadellas MO; Zara C; Haycox A; Campbell S; Godman B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):251-261. PubMed ID: 30696372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eunethta: further steps towards European cooperation on health technology assessment.
    Guegan EW; Huić M; Teljeur C
    Int J Technol Assess Health Care; 2014 Nov; 30(5):475-7. PubMed ID: 25747555
    [No Abstract]   [Full Text] [Related]  

  • 24. Health technology assessment and health care in the European Union.
    Banta D; Oortwijn W
    Int J Technol Assess Health Care; 2000; 16(2):626-35. PubMed ID: 10932427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transparency in drug regulation: public assessment reports in Europe and Australia.
    Papathanasiou P; Brassart L; Blake P; Hart A; Whitbread L; Pembrey R; Kieffer J
    Drug Discov Today; 2016 Nov; 21(11):1806-1813. PubMed ID: 27373773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
    Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
    Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stakeholder perspectives on cooperation in the clinical and nonclinical health technology assessment domains.
    Zimmermann G; Michelmore S; Hiligsmann M
    Int J Technol Assess Health Care; 2023 May; 39(1):e29. PubMed ID: 37212049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
    Beers E; Egberts TC; Leufkens HG; Jansen PA
    Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries.
    Németh B; Goettsch W; Kristensen FB; Piniazhko O; Huić M; Tesař T; Atanasijevic D; Lipska I; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):321-330. PubMed ID: 32500749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
    Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing a quality management system for the European Network for Health Technology Assessment (EUnetHTA): toward European HTA collaboration.
    Luhnen M; Ormstad SS; Willemsen A; Schreuder-Morel C; Helmink C; Ettinger S; Erdos J; Fathollah-Nejad R; Rehrmann M; Hviding K; Rüther A; Chalon PX
    Int J Technol Assess Health Care; 2021 Apr; 37(1):e59. PubMed ID: 33902782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing Health Technology Assessment to address health care system needs.
    Velasco Garrido M; Gerhardus A; Røttingen JA; Busse R
    Health Policy; 2010 Mar; 94(3):196-202. PubMed ID: 19889471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes.
    Tafuri G; Bélorgey C; Favaretti C; Frénoy E; Giorgio F; Guardian M; Hebborn A; Houÿez F; Imbert J; Lacombe D; Garcia JL; Garrett Z; Petelos E; Saeterdal I; Schuurman A; Skjöldebrand AL; Strammiello V; Widmer D; Willemsen A; Hedberg N
    Int J Technol Assess Health Care; 2020 Jun; 36(3):191-196. PubMed ID: 32317039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
    Erhel F; Scanff A; Naudet F
    Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the planned and ongoing project (POP) database a suitable tool to reduce duplication in the process of assessing new health technologies in the European Union? Preliminary experience in the context of the EUnetHTA Joint Action Project Framework (2010-2012).
    Vondeling H; Sandvei M
    Int J Technol Assess Health Care; 2014 Nov; 30(5):504-7. PubMed ID: 25747559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.